by Peter Ciszewski | Jan 4, 2021
Every potential Food and Drug Administration (FDA) approval for a rare disease treatment gives hope for patients and physicians. So far in 2021, there are over 25 therapies focused on rare diseases that have Prescription Drug User Fee Act (PDUFA) dates. PDUFA dates...
by Peter Ciszewski | Jan 1, 2021
Lori Leslie, MD, Assistant Professor at Hackensack Meridian School of Medicine, gives a brief overview of the current treatment landscape for chronic lymphocytic leukemia (CLL). CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow,...
by Peter Ciszewski | Dec 31, 2020
Othman Al-Sawaf, MD, from the University of Cologne, gives an overview of chronic lymphocytic leukemia (CLL). CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes, and blood. The disease is considered treatable, but...
by Peter Ciszewski | Dec 29, 2020
Andrew Kuykendall, MD, Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology discusses the typical treatment paradigm for polycythemia vera. Polycythemia vera is a rare blood disorder characterized by an increased concentration of...
by Peter Ciszewski | Dec 28, 2020
Thanos Zomas, MD, from Takeda Oncology, discusses 5-year follow-up data from the ECHELON-2 study presented at ASH 2020. The ECHELON-2 study was a double-blind, randomized, multicenter, phase 3 clinical trial that finished in 2018. It compared the efficacy and...
